XML 63 R14.htm IDEA: XBRL DOCUMENT
v2.4.0.6

SHARE CAPITAL | 12 Months Ended
--- | ---
Dec. 31, 2012
SHARE CAPITAL [Abstract] |
SHARE CAPITAL | NOTE 7 - SHARE CAPITAL
| a. | Rights of the Company's Common Stock
The Company's common stock is listed on the NYSE MKT and, since September 6, 2010, on the Tel Aviv Stock Exchange. Each share of Common Stock is entitled to one vote. The holders of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.
| b. | Stock based compensation
On December 14, 2006, the Board of Directors adopted the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan (the "Plan"). The Plan was amended on June 17, 2012 to increase the number of shares of common stock available under the plan from 9,741,655 shares to 11,341,655 shares. The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Sections 102 and 102A of the Israeli Income Tax Ordinance. Each option grant is subject to the track chosen by the Company, either Section 102 or Section 102A of the Israeli Income Tax Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company's accounts, in respect of options granted to employees under the Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For Israeli non-employees, the share option plan is subject to Section 3(i) of the Israeli Income Tax Ordinance. As of December 31, 2012, 176,986 shares of Common Stock remain available for grant under the Plan. For purposes of determining the fair value of the options and restricted stock granted to employees and non-employees, the Company's management uses the fair value of the Common Stock. From January 1, 2010 through December 31, 2012, the Company granted options and shares of restricted stock to certain employees and non-employees as follows:
| 1. | Options and restricted stock granted to employees:
| a) | Below is a table summarizing all of the options and restricted stock grants to employees for each of the three years in the three-year period ended December 31, 2012:
Year of grant |  |  | No. of options or restricted stock granted |  |  | Exercise price range |  |  | Vesting period |  | Fair value at grant (U.S. dollars in thousands) |  |  | Expiration period |
| 2010 |  |  |  | 1,016,000 |  |  |  | $6.90 |  |  | 3 years commencing upon achievement of a certain milestone |  | $ | 5,673 |  |  |  | 10 years |
| 2010 |  |  |  | 428,000 |  |  |  | $6.32-$9.66 |  |  | 4 years |  | $ | 2,147 |  |  |  | 10 years |
| 2012 |  |  |  | 400,000 |  |  |  | n/a |  |  | 3 years |  | $ | 2,288 |  |  |  | n/a |
| 2012 |  |  |  | 1,100,000 |  |  |  | n/a |  |  | 4 years |  | $ | 6,292 |  |  |  | n/a |
|  |  |  |  | 2,944,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Set forth below are grants made by the Company to employees (including related parties) during the three-year period ended December 31, 2012 (such grants appear in the table above):
| 1. | In February 2010, the Company's Board of Directors approved the grant of options to purchase 1,016,000 shares of Common Stock, in the aggregate, to the Company's Chief Executive Officer and certain officers and employees of the Company with an exercise price equal to $6.90 per share. The options vest quarterly over a three-year period commencing upon the FDA's approval of taliglucerase alfa. The Company treated the awards as performance-based awards and, given that the performance condition is outside the Company's control, concluded that the performance condition was not probable until the performance condition actually occurred. Upon the FDA's approval of taliglucerase alfa on May 1, 2012, the Company started recognizing share based compensation expenses related to such options. Share based compensation related to services performed from the date of grant of the respective options through the FDA approval date, were recognized on that date.
| 2. | In February 2010, the Company's Board of Directors approved the grant of options to purchase 160,000 shares of Common Stock with an exercise price equal to $6.81 per share to a new executive officer of the Company. The options expire on the tenth anniversary of the date of grant, unless terminated earlier. The first 25% of the options vest on the first anniversary of the date of grant and the remaining 75% vest in 12 equal tranches on a quarterly basis for three years thereafter.
| 3. | In September 2010, the Company's Board of Directors approved the grant of options to purchase 160,000 shares of Common Stock to a new executive officer of the Company with an exercise price equal to $7.55 per share and options to purchase 40,000 shares of Common Stock to a new employee of the Company with an exercise price equal to $6.32 per share. The options vest over a four-year period, with the first 25% vesting on the first anniversary of the applicable date of the grant and the remaining 75% vesting in equal tranches on a quarterly basis for a three-year period thereafter. The options expire on the tenth anniversary of the date of grant, unless terminated earlier.
| 4. | In November 2010, the Company's Board of Directors approved the grant of options to purchase 68,000 shares of Common Stock to a new officer of the Company with an exercise price equal to $9.66 per share. The options vest over a four-year period, with the first 25% vesting on the first anniversary of the applicable date of the grant and the remaining 75% vesting in equal tranches on a quarterly basis for a three-year period thereafter. The options expire on the tenth anniversary of the date of grant, unless terminated earlier.
| 5. | In September 2010, the Company's Board of Directors modified the terms of the options previously granted to an executive in 2001, by extending the life of the options until 2016. At the date of modification, all of the options were fully vested. The Company concluded that there was no incremental increase in the value of the awards and therefore no accounting charges need to be recorded in connection with the modifications.
| 6. | On July 16, 2012, the Company's Board of Directors approved the grant of 1,500,000 shares of restricted Common Stock to its officers and certain other employees. Of such restricted stock, 1,100,000 of the shares were issued to the Company's named executive officers and vest in 16 equal, quarterly increments over a four-year period, commencing upon the date of grant, and are subject to a 24-month lock-up period, commencing upon the applicable vesting dates. Immediately and automatically in the event of a Change in Control, as such term is defined in the Plan, as amended, all of the shares of restricted Common Stock issued to the named executive officers shall vest, and the lock-up periods shall terminate, subject to certain exceptions. The remaining 400,000 shares of restricted Common Stock were issued to other employees of the Company and vest in 12 equal, quarterly increments over a three-year period, commencing upon the date of grant. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $8.6 million.
| b) | The fair value of options and restricted stock granted during the years ended December 31, 2010 and 2012 were $7.8 million and $8.6 million respectively. The fair value of each option granted in 2010 is estimated on the date of grant using the Black-Scholes option-pricing model, with the following weighted average assumptions:
|  | 2010 |
Dividend yield |  |  | 0 | %
Expected volatility |  |  | 75 | %
Risk-free interest rate |  |  | 3.23 | %
Expected life - in years |  |  | 8.8 |
The expected volatility is based on the historical volatility of the Common Stock and those of comparable companies. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the stock options granted in dollar terms. The Company's management uses the contractual term or its expectations, based on historical incidence of option exercises, as applicable (during 2010 - using the simplified method), of each option as its expected life. The pre-vesting forfeiture rate of approximately 6.1% is estimated based on pre-vesting forfeiture experience. The fair value of the restricted stock is based on the Company's share price on the NYSE MKT on the grant date. The total unrecognized compensation cost of employee stock options and restricted stock at December 31, 2012 is approximately $7.0 million (net of forfeiture rate). The unrecognized compensation cost of employee stock options is expected to be recognized over a weighted average period of 1.1 years. The total cash received from employees as a result of employee stock option exercises for the years ended December 31, 2010, 2011 and 2012 was approximately $501,000, $277,000 and $1.2 million, respectively. The Company did not realize any tax benefit in connection with these exercises. During 2012, the Company issued 861,593 shares of Common Stock in connection with the exercise of 861,593 options by certain employees of the Company. The Company received cash proceeds equal to approximately $1.2 million in connection with such exercises.
| 2. | Options granted to consultants, directors, and other service providers:
As of December 31, 2012, the Company has recognized and recorded all compensation costs related to outstanding options for consultants, directors and other services providers. No cash was received from consultants as a result of consultant stock option exercises for the years ended December 31, 2010, and 2011 and approximately $39,000 was received during the year ended December 31, 2012. The Company did not realize any tax benefits in connection with these exercises. During 2012, the Company issued 326,267 shares of Common Stock in connection with the exercise of 326,267 options by consultants of the Company. The Company received cash proceeds equal to approximately $39,000 in connection with such exercise.
| 3. | A summary of share option plans, and related information, under all of the Company's equity incentive plans for the years ended December 31, 2010, 2011 and 2012 are as follows:
| a. | Options granted to employees:
|  | Year ended December 31, |
|  | 2010 |  |  | 2011 |  |  | 2012 |
|  |  |  |  | Weighted |  |  |  |  |  | Weighted |  |  |  |  |  | Weighted |
|  | Number |  |  | average |  |  | Number |  |  | average |  |  | Number |  |  | average |
|  | of |  |  | exercise |  |  | of |  |  | exercise |  |  | of |  |  | exercise |
|  | options |  |  | price |  |  | options |  |  | price |  |  | options |  |  | price |
Outstanding at beginning of year |  |  | 5,366,729 |  |  | $ | 2.476 |  |  |  | 6,367,979 |  |  | $ | 3.576 |  |  |  | 6,141,030 |  |  | $ | 3.563 |
Changes during the year: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Granted |  |  | 1,444,000 |  |  |  | 7.076 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Forfeited and Expired |  |  | 13,441 |  |  |  | 3.551 |  |  |  | 44,856 |  |  |  | 6.207 |  |  |  | 25,858 |  |  |  | 4.372 |
Exercised (*) |  |  | 429,309 |  |  |  | 1.602 |  |  |  | 182,093 |  |  |  | 1.652 |  |  |  | 861,593 |  |  |  | 1.346 |
Outstanding at end of year |  |  | 6,367,979 |  |  | $ | 3.576 |  |  |  | 6,141,030 |  |  | $ | 3.563 |  |  |  | 5,253,579 |  |  | $ | 3.923 |
Exercisable at end of year |  |  | 4,267,850 |  |  | $ | 2.183 |  |  |  | 4,647,834 |  |  | $ | 2.581 |  |  |  | 4,258,441 |  |  | $ | 3.201 |
| (*) | The total intrinsic value of options exercised during the years ended December 31, 2010, 2011 and 2012, was approximately $3.1 million, $1.3 million and $4.8 million, respectively.
| b. | Restricted stock granted to employees:
Year ended December 31, 2012
|  | Number of Restricted Shares |
Outstanding at beginning of year |  |  |
Changes during the year: |  |  |  |
Granted |  |  | 1,500,000 |
Forfeited |  |  | 3,208 |
Outstanding at end of year |  |  | 1,496,792 |
Exercisable at end of year |  |  | 102,084 |
| c. | Options granted to consultants, directors, and other service providers:
|  | Year ended December 31, |
|  | 2010 |  |  | 2011 |  |  | 2012 |
|  |  |  |  | Weighted |  |  |  |  |  | Weighted |  |  |  |  |  | Weighted |
|  | Number |  |  | average |  |  | Number |  |  | average |  |  | Number |  |  | average |
|  | of |  |  | exercise |  |  | of |  |  | exercise |  |  | of |  |  | exercise |
|  | options |  |  | price |  |  | options |  |  | price |  |  | options |  |  | price |
Outstanding at beginning of year |  |  | 1,438,692 |  |  | $ | 4.697 |  |  |  | 1,438,692 |  |  | $ | 4.697 |  |  |  | 1,238,692 |  |  | $ | 5.385 |
Changes during the year- Exercised (*) |  |  |  |  |  |  |  |  |  |  | 200,000 |  |  |  | 0.001 |  |  |  | 326,267 |  |  |  | 0.12 |
Outstanding at end of year |  |  | 1,438,692 |  |  | $ | 4.697 |  |  |  | 1,238,692 |  |  | $ | 5.385 |  |  |  | 912,425 |  |  | $ | 7.259 |
Exercisable at end of year |  |  | 1,421,734 |  |  | $ | 4.653 |  |  |  | 1,235,567 |  |  | $ | 5.385 |  |  |  | 912,425 |  |  | $ | 7.259 |
| (*) | The total intrinsic value of options exercised during the years ended December 31, 2010, 2011 and 2012, was approximately $0, $1.9 million and $2.3 million, respectively.
| d. | The following tables summarize information concerning outstanding and exercisable options and restricted stock as of December 31, 2012:
December 31, 2012 |
Options and restricted stock outstanding |  |  | Options exercisable and restricted stock vested |
Exercise prices |  |  | Number of Options and restricted stock outstanding at end of year |  |  | Weighted average remaining contractual life |  |  | Number of options exercisable and restricted stock vested at end of year |  |  | Weighted average remaining contractual life |
| n/a (Restricted Stock) |  |  |  | 1,496,792 |  |  |  | n/a |  |  |  | 102,084 |  |  |  | n/a |
$ | 0.001 |  |  |  | 719,207 |  |  |  | 2.54 |  |  |  | 719,207 |  |  |  | 2.54 |
$ | 0.120 |  |  |  | 447,850 |  |  |  | 1.05 |  |  |  | 447,850 |  |  |  | 1.05 |
$ | 0.399 |  |  |  | 23,087 |  |  |  | 1.92 |  |  |  | 23,087 |  |  |  | 1.92 |
$ | 0.972 |  |  |  | 996,353 |  |  |  | 3.44 |  |  |  | 996,353 |  |  |  | 3.44 |
$ | 2.350 |  |  |  | 40,000 |  |  |  | 5.82 |  |  |  | 40,000 |  |  |  | 5.82 |
$ | 2.650 |  |  |  | 402,882 |  |  |  | 6.15 |  |  |  | 396,744 |  |  |  | 6.15 |
$ | 3.020 |  |  |  | 50,000 |  |  |  | 5.10 |  |  |  | 50,000 |  |  |  | 5.10 |
$ | 5.000 |  |  |  | 1,708,000 |  |  |  | 5.10 |  |  |  | 1,708,000 |  |  |  | 5.10 |
$ | 6.810 |  |  |  | 160,000 |  |  |  | 7.10 |  |  |  | 110,000 |  |  |  | 7.10 |
$ | 6.900 |  |  |  | 1,003,083 |  |  |  | 7.15 |  |  |  | 168,083 |  |  |  | 7.15 |
$ | 7.550 |  |  |  | 160,000 |  |  |  | 7.66 |  |  |  | 90,000 |  |  |  | 7.66 |
$ | 9.660 |  |  |  | 68,000 |  |  |  | 7.83 |  |  |  | 34,000 |  |  |  | 7.83 |
$ | 16.700 |  |  |  | 387,542 |  |  |  | 3.99 |  |  |  | 387,542 |  |  |  | 3.99 |
|  |  |  |  | 7,662,796 |  |  |  |  |  |  |  | 5,272,950 |  |  |  |  |
The aggregate intrinsic value of the total outstanding and of total vested and exercisable options and restricted stock as of December 31, 2012 is approximately $19.7 million and $12.4 million, respectively.
| e. | The following table illustrates the effect of share-based compensation on the statement of operations:
|  | Year ended December 31, |
(U.S. dollars in thousands) |  | 2010 |  |  | 2011 |  |  | 2012 |
Cost of revenues |  |  |  |  |  |  |  |  |  | $ | 220 |
Research and development expenses |  | $ | 630 |  |  | $ | 422 |  |  |  | 4,756 |
General and administrative expenses |  |  | 652 |  |  |  | 464 |  |  |  | 2,775 |
|  | $ | 1,282 |  |  | $ | 886 |  |  | $ | 7,751 |
| c. | Public Offerings
| 1. | On March 23, 2011, the Company issued and sold 4,000,000 shares of Common Stock in an underwritten public offering at a price to the public of $5.50 per share. The net proceeds to the Company were approximately $20.6 million (net of underwriting commissions and issuance costs of $1.4 million)
| 2. | On February 22, 2012, the Company issued and sold 5,175,000 shares of Common Stock in an underwritten public offering at a price to the public of $5.25 per share. The net proceeds to the Company were approximately $25.4 million (net of underwriting commissions and issuance costs of $1.8 million).

X
- Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Preferred Stock -URI http://asc.fasb.org/extlink&oid=6521494 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section B -Paragraph 7, 11A -Chapter 1 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section C Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph d -Article 4 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 17: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707 Reference 18: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 19: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 20: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 21: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 22: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(d),(e)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 23: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Article 4 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration